anipharmaceuticals.com (ANIP): Rasio rega marang prakiraan pendapatan
ANI Pharmaceuticals (ANIP) asset protection is based on FDA licenses and proprietary manufacturing plants, which curbs competition. Analyzing the expected P/S value in GURU.Markets, we note that the current parameter is 0.70. This confirms the effectiveness of the strategy to release scarce medications and complex generics. Business stability is further complemented by strict environmental control of synthesis and the sustainable use of water resources.
Rincian metrik keuangan lan pasar ANI Pharmaceuticals Corp (ANIP)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- indikator nilai buku ekuitas:
- indikator total utang lan likuiditas perusahaan:
Utang marang Ekuitas ANI Pharmaceuticals|ANIP - Kewajiban jangka dawa marang ekuitas|Utang jangka cendhak marang modal ANI Pharmaceuticals|ANIP - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku ANI Pharmaceuticals Corp|ANIP - Utang jangka dawa perusahaan|Utang jangka cendhak perusahaan ANI Pharmaceuticals|Likuiditas cepet anipharmaceuticals.com
- rincian asil keuangan lan kelipatan valuasi:
ANIP - Penghasilan resik|Proyeksi bathi mangsa ngarep ANI Pharmaceuticals|ANIP - Pangali P/E|Pangali Forward P/E ANI Pharma|ANIP - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA ANI Pharmaceuticals Corp|ANIP - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan ANI Pharmaceuticals|ANIP - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan anipharmaceuticals.com|ANIP - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep ANI Pharmaceuticals
- indikator volume dodolan lan pendapatan:
Ringkesan analisis perusahaan:ANI Pharmaceuticals, Inc. ANIP
The forward P/S ratio assesses the market value of ANI Pharmaceuticals relative to expected revenue, allowing investors to filter out market noise and identify any actual overpayment for the asset. Given the patent protection of ANI Pharmaceuticals formulas, changes in the forward P/S reflect the business's ability to convert regulatory barriers into a stable cash flow, determining the long-term sustainability of the invested capital.
Pesaing ANI Pharmaceuticals
Multiplikator Forward P/S HLN (Haleon)|Multiplikator Forward P/S Kenvue Inc KVUE|VRNA - Rasio rega marang prakiraan pendapatan|MENS (Jyong Bio) - Kapitalisasi marang prakiraan pendapatan|LGND: Multiplikator Forward P/S|AMRX - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PRGO|ALVO: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Liquidia Technologies (LQDA)|GLPG: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S MNKD (MannKind Corporation)|Rega forward marang dodolan AMPH|Pacira BioSciences, Inc. - Multiplikator Forward P/S|SPRY - Multiplikator Forward P/S|Theravance (TBPH) - Rasio rega marang prakiraan pendapatan|Aquestive Corp - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan scPharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan Tectonic (TECX)|Multiplikator Forward P/S TNXP|Multiplikator Forward P/S sxtchina.com (SXTC)|Multiplikator Forward P/S EPRX (Eupraxia Pharmaceuticals Inc.)|BHST - Multiplikator forward rega marang pendapatan|eXoZymes Inc - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Oramed Pharmaceuticals|ENTX (enterabio.com) - Multiplikator forward rega marang pendapatan|MindWalk Holdings, Inc. (HYFT) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ABVC|CPIX (Cumberland Corp) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S QNTM|Rasio kapitalisasi marang dodolan sing dikarepake fibrogen.com|Multiplikator Forward P/S TELO (Telomir Pharmaceuticals, Inc.)|RANI - Multiplikator forward rega marang pendapatan|Synergy CHC Corporation - Multiplikator Forward P/S|RLYB - Multiplikator Forward P/S|lexariabioscience.com (LEXX) - Rasio rega marang prakiraan pendapatan|PULM (pulmatrix.com) - Rasio rega marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Pheton Holdings Limited|Aptorum (APM) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S LYRA|Multiplikator Forward P/S Impact BioMedical, Inc. (IBO)|Rasio rega marang prakiraan pendapatan TNF Pharmaceuticals, Inc. TNFA|YCBD: Kapitalisasi marang prakiraan pendapatan|PainReform - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Altamira Therapeutics CYTO|Lipella (LIPO) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan OPTN (OptiNose Corp)|Rasio rega marang prakiraan pendapatan Pieris Pharmaceuticals|procapsgroup.com - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S PTPI|QLI (Qilian International Holding Group) - Rega forward marang dodolan|Multiplikator Forward P/S SLRN (ACELYRIN, Inc.)|Multiplikator Forward P/S TFF Pharmaceuticals, Inc TFFP
